• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Prostaglandins and related compounds
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Eicosanoids Prostaglandins and related compounds

Prost-13-en-1-oic acid,11,15-dihydroxy-15-methyl-9-oxo-, (11a,13E,15S)- (9CI) and CAS No. 35700-26-6: A Comprehensive Overview

Prost-13-en-1-oic acid,11,15-dihydroxy-15-methyl-9-oxo-, (11a,13E,15S)- (9CI), identified by the CAS number 35700-26-6, is a compound of significant interest in the field of chemical and biomedical research. This compound belongs to a class of molecules known for their intricate structural features and potential biological activities. The detailed nomenclature reflects its complex molecular framework, which includes multiple functional groups and stereochemical configurations. Understanding such compounds requires a deep dive into their chemical properties, synthesis methodologies, and emerging applications in various scientific domains.

The structure of Prost-13-en-1-oic acid,11,15-dihydroxy-15-methyl-9-oxo-, (11a,13E,15S)- (9CI) is characterized by a polyketide backbone with specific hydroxyl and methyl substituents. The stereochemistry at the 11a, 13E, and 15S positions is crucial for its biological activity, making it a subject of intense study in medicinal chemistry. The presence of a carboxylic acid group at the 1-position and an oxo group at the 9-position further enhances its reactivity and potential utility in synthetic chemistry.

In recent years, there has been growing interest in polyketides due to their diverse biological activities. Research has highlighted their role as precursors to various pharmacologically active compounds. The compound CAS No. 35700-26-6 is no exception and has been explored for its potential in developing novel therapeutic agents. Studies have demonstrated its efficacy in modulating inflammatory pathways and other biological processes relevant to human health.

The synthesis of Prost-13-en-1-oic acid,11,15-dihydroxy-15-methyl-9-oxo-, (11a,13E,15S)- (9CI) involves multi-step organic reactions that require precise control over reaction conditions to achieve high yields and enantiomeric purity. Advances in synthetic methodologies have enabled researchers to access complex structures more efficiently than ever before. Techniques such as asymmetric synthesis and biocatalysis have played pivotal roles in constructing the intricate framework of this compound.

One of the most compelling aspects of this compound is its potential application in drug discovery. The unique structural features of CAS No. 35700-26-6 make it a valuable scaffold for designing molecules with enhanced binding affinity and selectivity towards target enzymes or receptors. Recent studies have shown promising results when this compound was used as a lead structure in virtual screening campaigns aimed at identifying novel bioactive molecules.

The biological activity of Prost-13-en-1-oic acid,11,15-dihydroxy-15-methyl-9-oxo-, (11a,13E,15S)- (9CI) has been extensively investigated in various cellular and animal models. Research has revealed its ability to interact with multiple signaling pathways involved in inflammation and immune responses. These findings have opened up new avenues for developing therapeutic strategies against chronic inflammatory diseases and autoimmune disorders.

The role of stereochemistry in determining the biological activity of this compound cannot be overstated. The specific arrangement of functional groups at the 11a, 13E, and 15S positions influences its interactions with biological targets. This highlights the importance of understanding molecular conformation and configurational effects in drug design.

Synthetic chemists have developed innovative approaches to modify the structure of CAS No. 35700-26-6 to enhance its pharmacological properties. By introducing additional functional groups or altering existing ones, researchers can fine-tune the molecule's activity profile. These modifications often lead to compounds with improved solubility, bioavailability, and metabolic stability.

The use of computational tools has revolutionized the process of drug discovery by enabling rapid screening of large libraries of compounds for potential bioactivity. Virtual screening methods have been particularly useful in identifying promising candidates like Prost-13-en-1-oic acid,11,15-dihydroxy-15-methyl-9-oxo-, (11a,13E,15S)- (9CI). These tools allow researchers to predict how different molecules will interact with biological targets based on their structural features.

In conclusion, the compound identified by CAS No. 35700-26-6 represents a fascinating example of how complex molecular structures can be leveraged for therapeutic purposes. Its intricate framework and diverse functional groups make it a valuable asset in the quest for novel pharmaceuticals. Ongoing research continues to uncover new applications for this compound and related derivatives.

• 363-24-6(Prostaglandin E2)
• 27415-25-4(8-Isoprostaglandin E2)
• 21003-46-3(8-Isoprostaglandin E1)
• 745-65-3(Prostaglandin E1)
• 24570-01-2(11-Epiprostaglandin E1)
• 38873-82-4(15(R)\u200b-\u200bProstaglandin E2)
• 38310-90-6(Prosta-5,13-dien-1-oicacid, 11,15-dihydroxy-9-oxo-, (5Z,11b,13E,15S)- (9CI))
• 36150-00-2(5-trans-Prostaglandin E2)
• 17968-82-0(Prostaglandin D1)
• 119008-22-9(5,6-DIHYDRO PGE3)